Abstract
Roxadustat, a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has been approved for the clinical management of anemia secondary to chronic kidney disease (CKD). Previously published reviews generally focus on single-organ or individual disease manifestations, and a comprehensive systematic overview regarding its potential indications across multiple organ systems remains lacking. Beyond stimulating erythropoiesis, roxadustat triggers extensive transcriptional cascades via systemic stabilization of hypoxia-inducible factor (HIF), thereby exerting pleiotropic pharmacological actions throughout diverse organs. Accumulating preclinical findings and emerging clinical data verify that roxadustat facilitates cardiovascular injury repair, confers neuroprotection, remodels systemic metabolism, maintains iron homeostasis and modulates the tumor microenvironment, conferring promising translational prospects for repurposing in various non-anemic disorders. Nevertheless, widespread activation of the HIF signaling pathway is accompanied by safety concerns including tumor progression promotion, adverse vascular events and endocrine dysfunctions. From a multisystem perspective, this review systematically integrates the molecular mechanisms, preclinical outcomes and translational evidence of roxadustat to fill the existing gaps in available literature. We further highlight that precise patient stratification and standardized long-term safety surveillance are indispensable to fully exploit the therapeutic potential of roxadustat beyond anemia treatment.
References
Bartnicki P. (2024). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease. Biomedicines, 12(8), 1884.
https://doi.org/10.3390/biomedicines12081884
Chen, J., Lin, X., Yao, C., Bingwa, L. A., Wang, H., Lin, Z., Jin, K., Zhuge, Q., & Yang, S. (2022). Transplantation of roxadustat-preconditioned bone marrow stromal cells improve neurological function recovery through enhancing grafted cell survival in ischemic stroke rats. CNS Neuroscience & Therapeutics, 28(10), 1519–1531.
https://doi.org/10.1111/CNS.13890
Chen, N., Hao, C., Liu, B.-C., Lin, H., Wang, C., Xing, C., Liang, X., Jiang, G., Liu, Z., Li, X., Zuo, L., Luo, L., Wang, J., Zhao, M., Liu, Z., Cai, G.-Y., Hao, L., Leong, R., Wang, C., … Yu, K.-H. P. (2019). Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine, 381(11), 1011–1022.
https://doi.org/10.1056/NEJMOA1901713
Chen, Y., Ohara, T., Hamada, Y., Wang, Y., Tian, M., Noma, K., Tazawa, H., Fujisawa, M., Yoshimura, T., & Matsukawa, A. (2025). HIF-PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses. Cancer Immunology, Immunotherapy, 74(7), 1–12.
https://doi.org/10.1007/S00262-025-04067-3
Chen, Y., Xu, J., Shi, S., Ma, W., Cui, W., Yan, R., & Lin, Y. (2024). A DNA nanostructure-HIF-1α inducer complex as novel nanotherapy against cisplatin-induced acute kidney injury. Cell Proliferation, 57(6).
https://doi.org/10.1111/CPR.13601
Dhillon, S. (2019). Roxadustat: First global approval. Drugs, 79(5), 563–572.
https://doi.org/10.1007/S40265-019-01077-1
Ding, K., Liu, Z., Ren, Y., Liu, H., & Fu, R. (2023). Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients. Annals of Hematology, 102(5), 1261–1263.
https://doi.org/10.1007/S00277-022-04997-3
Drüeke, T. B., & Massy, Z. A. (2019). Erythropoiesis-stimulating agents and mortality. Journal of the American Society of Nephrology, 30(6), 907–908.
https://doi.org/10.1681/ASN.2019030266
Fang, T., Ma, C., Yang, B., Zhao, M., Sun, L., & Zheng, N. (2025). Roxadustat improves diabetic myocardial injury by upregulating HIF-1α/UCP2 against oxidative stress. Cardiovascular Diabetology, 24(1).
https://doi.org/10.1186/S12933-025-02601-2
Fang, T., Ma, C., Zhang, Z., Sun, L., & Zheng, N. (2023). Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications. Frontiers in Pharmacology, 14.
https://doi.org/10.3389/FPHAR.2023.1088288
Fujimaki, A., Ohuchi, K., Takizawa, S., Murakami, T., Kurita, H., Hozumi, I., Wen, X., Kitamura, Y., Wu, Z., Maekawa, Y., & Inden, M. (2023). The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells. Scientific Reports, 13(1).
https://doi.org/10.1038/S41598-023-42903-7
Gáll, T., Pethő, D., Nagy, A., Póliska, S., Balla, G., & Balla, J. (2025). Prolyl hydroxylase inhibitor-mediated HIF activation drives transcriptional reprogramming in retinal pigment epithelium: Relevance to chronic kidney disease. Cells, 14(14), 1121.
https://doi.org/10.3390/CELLS14141121
Ganz, T., Locatelli, F., Arici, M., Akizawa, T., & Reusch, M. (2023). Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease. Journal of Clinical Medicine, 12(13).
https://doi.org/10.3390/jcm12134217
Gao, Y., Jiang, X., Yang, D., Guo, W., Wang, D., Gong, K., Peng, Y., Jiang, H., Shi, C., Duan, Y., Chen, Y., Han, J., & Yang, X. (2022). Roxadustat, a hypoxia-inducible factor 1α activator, attenuates both long- and short-term alcohol-induced alcoholic liver disease. Frontiers in Pharmacology, 13.
https://doi.org/10.3389/FPHAR.2022.895710
Henning, Y., Willbrand, K., Larafa, S., Weißenberg, G., Matschke, V., Theiss, C., Görtz, G. E., & Matschke, J. (2023). Cigarette smoke causes a bioenergetic crisis in RPE cells involving the downregulation of HIF-1α under normoxia. Cell Death Discovery, 9(1), 1–11.
https://doi.org/10.1038/S41420-023-01695-5
Hirai, K., Kaneko, S., Minato, S., Yanai, K., Hirata, M., Kitano, T., Ito, K., Ueda, Y., Ookawara, S., & Morishita, Y. (2023). Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease. Frontiers in Medicine, 10, 1071342.
https://doi.org/10.3389/FMED.2023.1071342
Hou, Y. P., Wang, C., Mao, X. Y., Zhang, M. Z., & Li, B. (2022). Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis. Journal of the Formosan Medical Association, 121(11).
https://doi.org/10.1016/j.jfma.2022.06.008
Huang, L. T., Chou, H. C., & Chen, C. M. (2021). Roxadustat attenuates hyperoxia-induced lung injury by upregulating proangiogenic factors in newborn mice. Pediatrics and Neonatology, 62(4), 369–378.
https://doi.org/10.1016/j.pedneo.2021.03.012
Iesari, S., Leclercq, I., Joudiou, N., Komuta, M., Daumerie, A., Ambroise, J., Dili, A., Feza-Bingi, N., Xhema, D., Bouzin, C., Gallez, B., Pisani, F., Bonaccorsi-Riani, E., & Gianello, P. (2021). Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection. Clinical Science, 135(19), 2285–2305.
https://doi.org/10.1042/CS20210183
Jacquemin, C., El Orch, W., Diaz, O., Lalande, A., Aublin-Gex, A., Jacolin, F., Toesca, J., Si-Tahar, M., Mathieu, C., Lotteau, V., Perrin-Cocon, L., & Vidalain, P. O. (2024). Pharmacological induction of the hypoxia response pathway in Huh7 hepatoma cells limits proliferation but increases resilience under metabolic stress. Cellular and Molecular Life Sciences, 81(1), 1–26.
https://doi.org/10.1007/S00018-024-05361-6
Jiao, K., Zhang, H., Li, B., Wang, Y., & Liu, J. (2024). Roxadustat protects oxidative stress and tissue injury in the brain induced by ischemic stroke via the HIF-1α/NRF2 axis. Journal of Neurosurgical Sciences, 68(6), 714–717.
https://doi.org/10.23736/S0390-5616.24.06329-X
Kabei, K., Tateishi, Y., Shiota, M., Osada-Oka, M., Nishide, S., Uchida, J., Nakatani, T., Matsunaga, S., Yamaguchi, T., Tomita, S., & Miura, K. (2020). Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG-4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model. Journal of Pharmacological Sciences, 142(3), 93–100.
https://doi.org/10.1016/J.JPHS.2019.12.002
Kasprzak, A. (2021). Insulin-like growth factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer. International Journal of Molecular Sciences, 22(12), 6434.
https://doi.org/10.3390/IJMS22126434
Kong, W., Wu, X., Shen, Z., Wang, M., Liu, X., Lin, X., Qiu, Y., Jiang, H., Chen, J., Lou, Y., & Huang, H. (2024). The efficacy and safety of roxadustat for the treatment of posttransplantation anemia: A randomized study. Kidney International Reports, 9(6), 1705–1717.
https://doi.org/10.1016/J.EKIR.2024.04.021
Lan, Q., Wang, K., Meng, Z., Lin, H., Zhou, T., Lin, Y., Jiang, Z., Chen, J., Liu, X., Lin, Y., & Lin, D. (2023). Roxadustat promotes hypoxia‐inducible factor‐1α/vascular endothelial growth factor signalling to enhance random skin flap survival in rats. International Wound Journal, 20(9), 3586.
https://doi.org/10.1111/IWJ.14235
Lewis, R., Bewersdorf, J. P., & Zeidan, A. M. (2021). Clinical management of anemia in patients with myelodysplastic syndromes: An update on emerging therapeutic options. Cancer Management and Research, 13, 645–657.
https://doi.org/10.2147/CMAR.S240600
Li, L., Li, A., Gan, L., & Zuo, L. (2023). Roxadustat improves renal osteodystrophy by dual regulation of bone remodeling. Endocrine, 79(1), 180–189.
https://doi.org/10.1007/S12020-022-03199-1
Li, L., Li, A., Zhu, L., Gan, L., & Zuo, L. (2022). Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway. Journal of Orthopaedic Surgery and Research, 17(1), 1–15.
https://doi.org/10.1186/s13018-022-03162-w
Li, N., Cui, W., Mu, D., Shi, X., Gao, L., Liu, S., Wang, H., Jiang, C., & Hu, Y. (2024). Effects of roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: A retrospective study. International Journal of Medical Sciences, 21(10), 1806–1813.
https://doi.org/10.7150/IJMS.97599
Li, Q., & Nik Ramli, N. N. (2025). Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) inhibitors: a therapeutic Double-Edged Sword in immunity and inflammation. Journal of Molecular Pathology, 6(4), 25.
https://doi.org/10.3390/jmp6040025
Li, X., Jiang, S., Gu, X., Liu, X., Shang, S., Zhang, J., Pang, K., & Li, W. (2024). Assessment of the safety of roxadustat for cardiovascular events in chronic kidney disease-related anemia using meta-analysis and bioinformatics. Frontiers in Pharmacology, 15.
https://doi.org/10.3389/FPHAR.2024.1380326
Li, X., & Lindholm, B. (2022). Cardiovascular risk prediction in chronic kidney disease. American Journal of Nephrology, 53(10), 730–739.
https://doi.org/10.1159/000528560
Li, Z. L., Tu, Y., & Liu, B. C. (2020). Treatment of renal anemia with roxadustat: Advantages and achievement. Kidney Diseases, 6(2), 65–73.
https://doi.org/10.1159/000504850
Lin, Q., Li, S., Jiang, N., Jin, H., Shao, X., Zhu, X., Wu, J., Zhang, M., Zhang, Z., Shen, J., Zhou, W., Gu, L., Lu, R., & Ni, Z. (2021). Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy. Autophagy, 17(10), 2975–2990.
https://doi.org/10.1080/15548627.2020.1848971
Liu, Y. F., Hu, R., Zhang, L. F., Fan, Y., Xiao, J. F., & Liao, X. Z. (2022). Effects of dexmedetomidine on cognitive dysfunction and neuroinflammation via the HDAC2/HIF-1α/PFKFB3 axis in a murine model of postoperative cognitive dysfunction. Journal of Biochemical and Molecular Toxicology, 36(6).
https://doi.org/10.1002/JBT.23044
Long, G., Chen, H., Wu, M., Li, Y., Gao, L., Huang, S., Zhang, Y., Jia, Z., & Xia, W. (2020). Antianemia drug roxadustat (FG-4592) protects against doxorubicin-induced cardiotoxicity by targeting antiapoptotic and antioxidative pathways. Frontiers in Pharmacology, 11.
https://doi.org/10.3389/FPHAR.2020.01191
Lu, S., Wu, J., Jiang, J., Guo, Q., Yu, Y., Liu, Y., Zhang, H., Qian, L., Dai, X., Xie, Y., Fu, T., Lee, T., Lu, Y., Ma, R., & Eisner, M. D. (2025). Efficacy and safety of roxadustat for anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, open-label, active-controlled phase III study. Journal of Clinical Oncology, 43(2), 143–153.
https://doi.org/10.1200/JCO.23.02742
Ma, X., Dong, Z., Liu, J., Ma, L., Sun, X., Gao, R., Pan, L., Zhang, J., Dilan, A., An, J., Hu, K., Sun, A., & Ge, J. (2022). β-hydroxybutyrate exacerbates hypoxic injury by inhibiting HIF-1α-dependent glycolysis in cardiomyocytes—Adding fuel to the fire? Cardiovascular Drugs and Therapy, 36(3), 383–397.
https://doi.org/10.1007/S10557-021-07267-Y
Madai, S., Kilic, P., Schmidt, R. M., Bas-Orth, C., Korff, T., Büttner, M., Klinke, G., Poschet, G., Marti, H. H., & Kunze, R. (2024). Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism. Theranostics, 14(7), 2856–2880.
https://doi.org/10.7150/THNO.88223
Mäkinen, S., Sree, S., Ala-Nisula, T., Kultalahti, H., Koivunen, P., & Koistinen, H. A. (2024). Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men. Diabetologia, 67(9), 1943–1954.
https://doi.org/10.1007/S00125-024-06185-6
McDonnell, T., & Kalra, P. A. (2025). Iron in chronic kidney disease and end-stage kidney disease-current trends and future direction. British Journal of Hospital Medicine, 86(2).
https://doi.org/10.12968/HMED.2024.0619
Mendoza-Reinoso, V., Schnepp, P. M., Baek, D. Y., Rubin, J. R., Schipani, E., Keller, E. T., McCauley, L. K., & Roca, H. (2022). Bone marrow macrophages induce inflammation by efferocytosis of apoptotic prostate cancer cells via HIF-1α stabilization. Cells, 11(23).
https://doi.org/10.3390/CELLS11233712
Miao, A. F., Liang, J. X., Yao, L., Han, J. L., & Zhou, L. J. (2021). Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation. Renal Failure, 43(1), 803.
https://doi.org/10.1080/0886022X.2021.1915801
Moreton, N., Puzio, M., McCormack, J., & O’Connor, J. J. (2023). The effects of prolyl hydroxylase inhibition during and post, hypoxia, oxygen glucose deprivation and oxidative stress, in isolated rat hippocampal slices. Brain Research Bulletin, 205.
https://doi.org/10.1016/j.brainresbull.2023.110822
Naito, H., Iba, T., & Takakura, N. (2020). Mechanisms of new blood-vessel formation and proliferative heterogeneity of endothelial cells. International Immunology, 32(5), 295–305.
https://doi.org/10.1093/INTIMM/DXAA008
Nik Ramli, N. N., Omar, N., Husin, A., Ismail, Z., & Siran, R. (2015). Preconditioning effect of (S)-3,5-dihydroxyphenylglycine on ischemic injury in middle cerebral artery occluded Sprague-Dawley rats. Neuroscience letters, 588, 137–141.
https://doi.org/10.1016/j.neulet.2014.12.062
Nishide, S., Uchida, J., Matsunaga, S., Tokudome, K., Yamaguchi, T., Kabei, K., Moriya, T., Miura, K., Nakatani, T., & Tomita, S. (2020). Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice. Journal of Pharmacological Sciences, 143(2), 122–126.
https://doi.org/10.1016/J.JPHS.2020.02.010
Nishioku, T., Nakao, S., Anzai, R., Hiramatsu, S., Momono, A., Moriyama, M., Nakao, M., & Terazono, A. (2025). HIF-1α stabilization in osteoclasts induces the expression of aerobic glycolysis-related proteins GLUT1, LDHA, and MCT4. Journal of Pharmacological Sciences, 158(4), 336–342.
https://doi.org/10.1016/J.JPHS.2025.05.017
Nsiah, N. Y., Morgan, A. B., Donkor, N., & Inman, D. M. (2023). Long-term HIF-1α stabilization reduces respiration, promotes mitophagy, and results in retinal cell death. Scientific Reports, 13(1), 20541.
https://doi.org/10.1038/S41598-023-47942-8
Qannita, R. A., Alalami, A. I., Harb, A. A., Aleidi, S. M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M. A., Alzoubi, K. H., Semreen, M. H., Hudaib, M., & Bustanji, Y. (2024). Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: Emerging therapeutic strategies and pathway regulation. Pharmaceuticals, 17(2).
https://doi.org/10.3390/ph17020195
Seeley, T. W., Sternlicht, M. D., Klaus, S. J., Neff, T. B., & Liu, D. Y. (2017). Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia, 5, 1–9.
https://doi.org/10.2147/HP.S130526
Semenza, G. L. (2001). HIF-1 and mechanisms of hypoxia sensing. Current Opinion in Cell Biology, 13(2), 167–171.
https://doi.org/10.1016/S0955-0674(00)00194-0
Shi, Y., Zhao, Y., Liang, W., Zhang, B., Kang, R., Yang, W., Zhao, X., & Zhang, F. (2024). A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses. Annals of Hematology, 103(8), 2757–2763.
https://doi.org/10.1007/S00277-024-05799-5
Stolze, I. P., Mole, D. R., & Ratcliffe, P. J. (2006). Regulation of HIF: Prolyl hydroxylases. Novartis Foundation Symposium, 272, 15–25.
https://doi.org/10.1002/9780470035009.ch3
Su, X., Xie, Y., Zhang, J., Li, M., Zhang, Q., Jin, G., & Liu, F. (2022). HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Cell Death and Disease, 13(10).
https://doi.org/10.1038/S41419-022-05304-8
Sung, P. H., Yue, Y., Chen, Y. L., Chiang, J. Y., Cheng, B. C., Yang, C. C., Chai, H. T., & Yip, H. K. (2024). Combined dapagliflozin and roxadustat effectively protected heart and kidney against cardiorenal syndrome-induced damage in rodent through activation of cell stress-Nfr2/ARE signalings and stabilizing HIF-1α. Biomedicine and Pharmacotherapy, 180.
https://doi.org/10.1016/j.biopha.2024.117567
Vaupel, P., & Multhoff, G. (2021). Revisiting the Warburg effect: Historical dogma versus current understanding. Journal of Physiology, 599(6), 1745–1757.
https://doi.org/10.1113/JP278810
Wang, D., Gu, C., Lv, M., & Wang, Y. (2023). Roxadustat reduced the risk of perioperative complication arising from the treatment of cardiac paraganglioma: A case report. Asian Journal of Surgery, 46(9), 3899–3901.
https://doi.org/10.1016/J.ASJSUR.2023.03.159
Wang, L., Wu, Y., Li, Y., You, L., Liu, X., Wang, Z., Xiao, J., Zhang, S., Xu, T., Wang, X., Li, Q., Hu, C., Xu, G., & Liu, S. (2022). Effect of roxadustat on serum metabolome and lipidome in patients with end-stage renal disease and erythropoiesis-stimulating agent resistance. Annals of Translational Medicine, 10(19), 1069–1069.
https://doi.org/10.21037/ATM-22-4451
Wang, L., Yin, H., Yang, L., Zhang, F., Wang, S., & Liao, D. (2022). The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: A meta-analysis. Frontiers in Pharmacology, 13, 779694.
https://doi.org/10.3389/FPHAR.2022.779694
Wang, Y., Xiao, M., Cai, F., Li, Y., Shi, T., Zhou, X., Tian, S., & Huang, D. (2024). Roxadustat ameliorates vascular calcification in CKD rats by regulating HIF-2α/HIF-1α. Environmental Toxicology, 39(4), 2363–2373.
https://doi.org/10.1002/TOX.24116
Xie, R., Fang, X., Zheng, X., Lv, W., Li, Y., Ibrahim Rage, H., He, Q., Zhu, W., & Cui, T. (2019). Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation. Biomedicine and Pharmacotherapy, 118.
https://doi.org/10.1016/j.biopha.2019.109175
Xu, L., Hu, Q., Yang, C., Chen, M., & Han, B. (2024). Efficacy and safety of roxadustat in the treatment of refractory non-severe aplastic anemia. Chinese Journal of Hematology, 45(3), 264–270.
https://doi.org/10.3760/CMA.J.CN121090-20230902-00101
Xu, T., Ruan, Y., Liu, N., Wang, Y., Zang, X., Ma, Y., Qi, H., Mi, X., Yu, G., Zhang, C., Huang, X., Xie, J., Chen, N., & Ren, H. (2025). Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia: A multicenter, randomized, controlled clinical study. Renal Failure, 47(1), 2460726.
https://doi.org/10.1080/0886022X.2025.2460726
Yang, C., Zhong, Z. F., Wang, S. P., Vong, C. T., Yu, B., & Wang, Y. T. (2021). HIF-1: Structure, biology and natural modulators. Chinese Journal of Natural Medicines, 19(7), 521–527.
https://doi.org/10.1016/S1875-5364(21)60051-1
Yang, D., Gao, Y., Yin, Z., Wang, X., Meng, X., Zou, T., Duan, Y., Chen, Y., Liao, C., Xie, Z., Fan, X., Sun, L., Han, J., & Yang, X. (2023). Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway. Acta Pharmacologica Sinica, 44(2), 308–320.
https://doi.org/10.1038/S41401-022-00941-3
Yang, H., Wu, Y., Cheng, M., Zhang, M., Qiu, X., Liu, S., & Zhang, M. (2023). Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation. Nephrology Dialysis Transplantation, 38(4), 858–875.
https://doi.org/10.1093/NDT/GFAC308
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001). HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9630–9635.
https://doi.org/10.1073/PNAS.181341498
Yu, J., Wang, S., Shi, W., Zhou, W., Niu, Y., Huang, S., Zhang, Y., Zhang, A., & Jia, Z. (2021). Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. JCI Insight, 6(18).
https://doi.org/10.1172/JCI.INSIGHT.133690
Zaruba, M. M., Staggl, S., Ghadge, S. K., Maurer, T., Gavranovic-Novakovic, J., Jeyakumar, V., Schönherr, P., Wimmer, A., Pölzl, G., Bauer, A., & Messner, M. (2024). Roxadustat attenuates adverse remodeling following myocardial infarction in mice. Cells, 13(13).
https://doi.org/10.3390/CELLS13131074
Zhang, M., Dong, R., Yuan, J., Da, J., Zha, Y., & Long, Y. (2022). Roxadustat (FG-4592) protects against ischaemia/reperfusion-induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice. Clinical and Experimental Pharmacology and Physiology, 49(2), 311–318.
https://doi.org/10.1111/1440-1681.13601
Zhang, W., Li, Y., & Wang, J. G. (2024). Hypertension induced by hypoxia-inducible factor prolyl hydroxylase inhibitors in treating anemia in patients with chronic kidney disease: A mini-review. Journal of Clinical Hypertension, 26(12), 1375–1383.
https://doi.org/10.1111/JCH.14924
Zheng, F. F., Zhao, Y. Y., Cai, L. J., Wu, G., Wang, J. N., & Zhao, M. Z. (2023). Roxadustat protects rat renal tubular epithelial cells from hypoxia-induced injury through the TGF-β1/Smad3 signaling pathway. European Review for Medical and Pharmacological Sciences, 27(24), 11370–11382.
https://doi.org/10.26355/EURREV_202312_34577
Zhu, X., Jiang, L., Wei, X., Long, M., & Du, Y. (2022). Roxadustat: Not just for anemia. Frontiers in Pharmacology, 13.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Qinyun Li, Long Cheng, Nik Nasihah Nik Ramli